Condition: Severe Lower Limb Ischemia · Sponsor: Amur State Medical Academy
GENEVA is the world's first multicenter, randomized, prospective, controlled trial of the clinical effectiveness of best endovascular treatment versus best endovascular treatment combined with gene therapy for severe lower limb ischemia (Rutherford categories 4 and 5). The researchers hypothesized that the combination treatment would significantly reduce the number of re-interventions on the operated segment and high amputations, and also significantly increase the time interval between re-interventions.
This description comes directly from the study's public registry record.
Alrxander Korotkikh, PhD · +7 (922) 079-06-22 · dr.alex.korotkikh@gmail.cpm
Sergey Radaev · +70(969) 255-14-30 · radaev@nextgene.ru
Always discuss trial participation with your own doctor first.
| Amur State Medical Academy | Blagoveshchensk, Amur Oblast, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06473740